Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.
Identifieur interne : 002158 ( Ncbi/Checkpoint ); précédent : 002157; suivant : 002159Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.
Auteurs : Laurence Fardet [France] ; Pierre-Emmanuel Stoebner ; Herve Bachelez ; Vincent Descamps ; Delphine Kerob ; Laurent Meunier ; Michel Dandurand ; Patrice Morel ; Celeste LebbeSource :
- Cancer [ 0008-543X ] ; 2006.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques d'origine végétale (usage thérapeutique), Femelle, Humains, Inhibiteurs de l'angiogenèse (usage thérapeutique), Mâle, Paclitaxel (usage thérapeutique), Sarcome de Kaposi (anatomopathologie), Sarcome de Kaposi (traitement médicamenteux), Sujet âgé, Sujet âgé de 80 ans ou plus, Séronégativité VIH, Taxoïdes (usage thérapeutique), Tumeurs cutanées (anatomopathologie), Tumeurs cutanées (traitement médicamenteux).
- MESH :
- anatomopathologie : Sarcome de Kaposi, Tumeurs cutanées.
- traitement médicamenteux : Sarcome de Kaposi, Tumeurs cutanées.
- usage thérapeutique : Antinéoplasiques d'origine végétale, Inhibiteurs de l'angiogenèse, Paclitaxel, Taxoïdes.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Séronégativité VIH.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors (therapeutic use), Antineoplastic Agents, Phytogenic (therapeutic use), Female, HIV Seronegativity, Humans, Male, Middle Aged, Paclitaxel (therapeutic use), Sarcoma, Kaposi (drug therapy), Sarcoma, Kaposi (pathology), Skin Neoplasms (drug therapy), Skin Neoplasms (pathology), Taxoids (therapeutic use).
- MESH :
- chemical , therapeutic use : Angiogenesis Inhibitors, Antineoplastic Agents, Phytogenic, Paclitaxel, Taxoids.
- drug therapy : Sarcoma, Kaposi, Skin Neoplasms.
- pathology : Sarcoma, Kaposi, Skin Neoplasms.
- Adult, Aged, Aged, 80 and over, Female, HIV Seronegativity, Humans, Male, Middle Aged.
Abstract
Kaposi sarcoma (KS) is an angioproliferative disease that may represent a difficult therapeutic challenge in disseminated stages. The efficacy of taxanes (paclitaxel and docetaxel), as agents with antiangiogenic properties, has been described previously in the treatment of patients with acquired immunodeficiency syndrome (AIDS)-associated KS but remains unknown in the treatment of patients with refractory or life-threatening KS without human immunodeficiency (HIV) infection.
DOI: 10.1002/cncr.21791
PubMed: 16534786
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003A54
- to stream PubMed, to step Curation: 003A54
- to stream PubMed, to step Checkpoint: 003A54
- to stream Ncbi, to step Merge: 002158
- to stream Ncbi, to step Curation: 002158
Links to Exploration step
pubmed:16534786Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.</title><author><name sortKey="Fardet, Laurence" sort="Fardet, Laurence" uniqKey="Fardet L" first="Laurence" last="Fardet">Laurence Fardet</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Hospital Saint-Louis, Paris, France. lfardet@club-internet.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Hospital Saint-Louis, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Stoebner, Pierre Emmanuel" sort="Stoebner, Pierre Emmanuel" uniqKey="Stoebner P" first="Pierre-Emmanuel" last="Stoebner">Pierre-Emmanuel Stoebner</name></author><author><name sortKey="Bachelez, Herve" sort="Bachelez, Herve" uniqKey="Bachelez H" first="Herve" last="Bachelez">Herve Bachelez</name></author><author><name sortKey="Descamps, Vincent" sort="Descamps, Vincent" uniqKey="Descamps V" first="Vincent" last="Descamps">Vincent Descamps</name></author><author><name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name></author><author><name sortKey="Meunier, Laurent" sort="Meunier, Laurent" uniqKey="Meunier L" first="Laurent" last="Meunier">Laurent Meunier</name></author><author><name sortKey="Dandurand, Michel" sort="Dandurand, Michel" uniqKey="Dandurand M" first="Michel" last="Dandurand">Michel Dandurand</name></author><author><name sortKey="Morel, Patrice" sort="Morel, Patrice" uniqKey="Morel P" first="Patrice" last="Morel">Patrice Morel</name></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16534786</idno><idno type="pmid">16534786</idno><idno type="doi">10.1002/cncr.21791</idno><idno type="wicri:Area/PubMed/Corpus">003A54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003A54</idno><idno type="wicri:Area/PubMed/Curation">003A54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003A54</idno><idno type="wicri:Area/PubMed/Checkpoint">003A54</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003A54</idno><idno type="wicri:Area/Ncbi/Merge">002158</idno><idno type="wicri:Area/Ncbi/Curation">002158</idno><idno type="wicri:Area/Ncbi/Checkpoint">002158</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.</title><author><name sortKey="Fardet, Laurence" sort="Fardet, Laurence" uniqKey="Fardet L" first="Laurence" last="Fardet">Laurence Fardet</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Hospital Saint-Louis, Paris, France. lfardet@club-internet.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Hospital Saint-Louis, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Stoebner, Pierre Emmanuel" sort="Stoebner, Pierre Emmanuel" uniqKey="Stoebner P" first="Pierre-Emmanuel" last="Stoebner">Pierre-Emmanuel Stoebner</name></author><author><name sortKey="Bachelez, Herve" sort="Bachelez, Herve" uniqKey="Bachelez H" first="Herve" last="Bachelez">Herve Bachelez</name></author><author><name sortKey="Descamps, Vincent" sort="Descamps, Vincent" uniqKey="Descamps V" first="Vincent" last="Descamps">Vincent Descamps</name></author><author><name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name></author><author><name sortKey="Meunier, Laurent" sort="Meunier, Laurent" uniqKey="Meunier L" first="Laurent" last="Meunier">Laurent Meunier</name></author><author><name sortKey="Dandurand, Michel" sort="Dandurand, Michel" uniqKey="Dandurand M" first="Michel" last="Dandurand">Michel Dandurand</name></author><author><name sortKey="Morel, Patrice" sort="Morel, Patrice" uniqKey="Morel P" first="Patrice" last="Morel">Patrice Morel</name></author><author><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name></author></analytic><series><title level="j">Cancer</title><idno type="ISSN">0008-543X</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Antineoplastic Agents, Phytogenic (therapeutic use)</term><term>Female</term><term>HIV Seronegativity</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Paclitaxel (therapeutic use)</term><term>Sarcoma, Kaposi (drug therapy)</term><term>Sarcoma, Kaposi (pathology)</term><term>Skin Neoplasms (drug therapy)</term><term>Skin Neoplasms (pathology)</term><term>Taxoids (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques d'origine végétale (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term><term>Mâle</term><term>Paclitaxel (usage thérapeutique)</term><term>Sarcome de Kaposi (anatomopathologie)</term><term>Sarcome de Kaposi (traitement médicamenteux)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Séronégativité VIH</term><term>Taxoïdes (usage thérapeutique)</term><term>Tumeurs cutanées (anatomopathologie)</term><term>Tumeurs cutanées (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Antineoplastic Agents, Phytogenic</term><term>Paclitaxel</term><term>Taxoids</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Sarcome de Kaposi</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sarcoma, Kaposi</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Sarcoma, Kaposi</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sarcome de Kaposi</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques d'origine végétale</term><term>Inhibiteurs de l'angiogenèse</term><term>Paclitaxel</term><term>Taxoïdes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>HIV Seronegativity</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Séronégativité VIH</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Kaposi sarcoma (KS) is an angioproliferative disease that may represent a difficult therapeutic challenge in disseminated stages. The efficacy of taxanes (paclitaxel and docetaxel), as agents with antiangiogenic properties, has been described previously in the treatment of patients with acquired immunodeficiency syndrome (AIDS)-associated KS but remains unknown in the treatment of patients with refractory or life-threatening KS without human immunodeficiency (HIV) infection.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Bachelez, Herve" sort="Bachelez, Herve" uniqKey="Bachelez H" first="Herve" last="Bachelez">Herve Bachelez</name><name sortKey="Dandurand, Michel" sort="Dandurand, Michel" uniqKey="Dandurand M" first="Michel" last="Dandurand">Michel Dandurand</name><name sortKey="Descamps, Vincent" sort="Descamps, Vincent" uniqKey="Descamps V" first="Vincent" last="Descamps">Vincent Descamps</name><name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name><name sortKey="Lebbe, Celeste" sort="Lebbe, Celeste" uniqKey="Lebbe C" first="Celeste" last="Lebbe">Celeste Lebbe</name><name sortKey="Meunier, Laurent" sort="Meunier, Laurent" uniqKey="Meunier L" first="Laurent" last="Meunier">Laurent Meunier</name><name sortKey="Morel, Patrice" sort="Morel, Patrice" uniqKey="Morel P" first="Patrice" last="Morel">Patrice Morel</name><name sortKey="Stoebner, Pierre Emmanuel" sort="Stoebner, Pierre Emmanuel" uniqKey="Stoebner P" first="Pierre-Emmanuel" last="Stoebner">Pierre-Emmanuel Stoebner</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Fardet, Laurence" sort="Fardet, Laurence" uniqKey="Fardet L" first="Laurence" last="Fardet">Laurence Fardet</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002158 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 002158 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:16534786
|texte= Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:16534786" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |